1-(naphthalen-1-yl)-2-phenylethan-1-amine

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 1-(naphthalen-1-yl)-2-phenylethan-1-amine
• 英文别名: 1-(naphthalen-1-yl)-2-phenylethanamine；1-[1]naphthyl-2-phenyl-ethylamine；1-[1]Naphthyl-2-phenyl-aethylamin；1-Naphthalen-1-yl-2-phenylethanamine
• 化学式: C₁₈H₁₇N
• 分子量: 247.34
• InChiKey: PXMQLPWDLKAKAK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(naphthalen-1-yl)-2-phenylethan-1-amine 在 盐酸 、 sodium cyanide 、 palladium 10% on activated carbon 、 氢气 作用下， 以 四氢呋喃 、 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 20.0~145.0 ℃ 、275.8 kPa 条件下， 反应 62.0h， 生成 (±)-methyl 1-(1-(naphthalen-1-yl)-2-phenylethyl)-piperidine-4-carboxylate
  参考文献：
  名称：

  X-ray Structural and Biological Evaluation of a Series of Potent and Highly Selective Inhibitors of Human Coronavirus Papain-like Proteases

  摘要：

  Structure-guided design was used to generate a series of noncovalent inhibitors with nanomolar potency against the papain-like protease (PLpro) from the SARS coronavirus (CoV). A number of inhibitors exhibit antiviral activity against SARS-CoV infected Vero E6 cells and broadened specificity toward the homologous PLP2 enzyme from the human coronavirus NL63. Selectivity and cytotoxicity studies established a more than 100-fold preference for the coronaviral enzyme over homologous human deubiquitinating enzymes (DUBs), and no significant cytotoxicity in Vero E6 and HEK293 cell lines is observed. X-ray structural analyses of inhibitor-bound crystal structures revealed subtle differences between binding modes of the initial benzodioxolane lead (15g) and the most potent analogues 3k and 3j, featuring a monofluoro substitution at para and meta positions of the benzyl ring, respectively. Finally, the less lipophilic bis(amide) 3e and methoxypyridine 5c exhibit significantly improved metabolic stability and are viable candidates for advancing to in vivo studies.

  DOI：

  10.1021/jm401712t
• 作为产物：
  描述：

  氰基萘 在 吡啶 、 盐酸 、 3-氯苯甲酰乙腈 作用下， 以 乙醚 、 水 为溶剂， 生成 1-(naphthalen-1-yl)-2-phenylethan-1-amine
  参考文献：
  名称：

  X-ray Structural and Biological Evaluation of a Series of Potent and Highly Selective Inhibitors of Human Coronavirus Papain-like Proteases

  摘要：

  Structure-guided design was used to generate a series of noncovalent inhibitors with nanomolar potency against the papain-like protease (PLpro) from the SARS coronavirus (CoV). A number of inhibitors exhibit antiviral activity against SARS-CoV infected Vero E6 cells and broadened specificity toward the homologous PLP2 enzyme from the human coronavirus NL63. Selectivity and cytotoxicity studies established a more than 100-fold preference for the coronaviral enzyme over homologous human deubiquitinating enzymes (DUBs), and no significant cytotoxicity in Vero E6 and HEK293 cell lines is observed. X-ray structural analyses of inhibitor-bound crystal structures revealed subtle differences between binding modes of the initial benzodioxolane lead (15g) and the most potent analogues 3k and 3j, featuring a monofluoro substitution at para and meta positions of the benzyl ring, respectively. Finally, the less lipophilic bis(amide) 3e and methoxypyridine 5c exhibit significantly improved metabolic stability and are viable candidates for advancing to in vivo studies.

  DOI：

  10.1021/jm401712t

文献信息

• Alkaline-Metal-Catalyzed One-Pot Aminobenzylation of Aldehydes with Toluenes
  作者：Guoqing Liu、Patrick J. Walsh、Jianyou Mao

  DOI：10.1021/acs.orglett.9b02737

  日期：2019.11.1

  A novel and easily accessible MN(SiMe3)2 (M = Li or Na)/Cs2CO3 co-catalyzed benzylation of in situ generated N-(trimethylsilyl) aldimines with toluene derivatives has been successfully developed. The catalyst exhibits high chemoselectivity for deprotonation of toluenes at the benzylic position. The utility of this system is exemplified by the one-pot synthesis of a diverse array of bioactive 1,2-diarylethylamines

  已成功开发了一种新颖且易于使用的MN（SiMe 3）2（M = Li或Na）/ Cs 2 CO 3催化原位生成的N-（三甲基甲硅烷基）亚胺与甲苯衍生物的苄基化反应。该催化剂对苄基位置的甲苯去质子表现出高化学选择性。一锅合成具有优异效率和宽泛的官能团耐受性的各种生物活性1,2-二芳基乙胺的例子说明了该系统的实用性。
• THERAPEUTIC FLUOROETHYL UREAS
  申请人：Chow Ken

  公开号：US20070270498A1

  公开（公告）日：2007-11-22

  Compounds of the formula or a pharmaceutically acceptable salt thereof or a tautomer thereof, wherein A and B are as described herein, are useful for treating conditions afflicting mammals.

  该公式化合物或其药用盐或其互变异构体，其中A和B如本文所述，可用于治疗影响哺乳动物的疾病。
• [EN] PROPENOYL HYDRAZIDES<br/>[FR] HYDRAZIDES DE PROPENOYLE
  申请人：GEORGIA TECH RES INST

  公开号：WO2005080353A1

  公开（公告）日：2005-09-01

  The present disclosure provides compositions for inhibiting proteases, methods for synthesizing the compositions, and methods of using the disclosed protease inhibitors. Aspects of the disclosure include a peptidyl propenoyl hydrazide compositions that inhibit proteases, for example cysteine proteases, either in vivo or in vitro.

  本公开提供了用于抑制蛋白酶的组合物、合成这些组合物的方法，以及使用所公开的蛋白酶抑制剂的方法。本公开的内容包括一种肽基丙烯酰肼组合物，可以抑制蛋白酶，例如半胱氨酸蛋白酶，无论是在体内还是体外。
• Propenoyl hydrazides
  申请人：Powers C. James

  公开号：US20050256058A1

  公开（公告）日：2005-11-17

  The present disclosure provides compositions for inhibiting proteases, methods for synthesizing the compositions, and methods of using the disclosed protease inhibitors. Aspects of the disclosure include a peptidyl propenoyl hydrazide compositions that inhibit proteases, for example cysteine proteases, either in vivo or in vitro.

  本公开提供了抑制蛋白酶的组合物，合成这些组合物的方法，以及使用所披露的蛋白酶抑制剂的方法。本公开的方面包括一种肽基丙烯酰肼组合物，其可以抑制体内或体外的蛋白酶，例如半胱氨酸蛋白酶。
• Catecholamine surrogates useful as B3 agonists
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：EP0659737A2

  公开（公告）日：1995-06-28

  Compounds of the formula or pharmaceutically acceptable salts thereof wherein: A is a bond, -(CH2)n- or -CH(B)-, where n is an integer of 1 to 3 and B is -CN, -CON(R9)R9' or -C02R7; R1 is lower alkyl, aryl or arylalkyl; R2 is hydrogen, hydroxy, alkoxy, -CH20H, cyano, -C(O)OR7 , -C02H, -CONH2, tetrazole, -CH2NH2 or halogen; R3 is hydrogen, alkyl, heterocycle or R4 is hydrogen, alkyl or B; R5, R5', R8, R8' or R8'' are independently hydrogen, alkoxy, lower alkyl, halogen, -OH, -CN, -(CH2)-nNR6COR7, -CON(R6)R6', -CON(R6)OR6', -C02R6, -SR7, -SOR7, -S02R7, -N(R6)SO2R1, -N(R6)R6', -NR6COR7, -OCH2CON(R6)R6', -OCH2CO2R7 or aryl; or R5 and R5' or R8 and R8' may together with the carbon atoms to which they are attached form an aryl or heterocycle; R6 and R6' are independently hydrogen or lower alkyl; and R7 is lower alkyl; R9 is hydrogen, lower alkyl, alkyl, cycloalkyl, arylalkyl, aryl, heteroaryl; or R9 and R9' may together with the nitrogen atom to which they are attached form a hetocycle; with the proviso that when A is a bond or -(CH2)n and R3 is hydrogen or unsubstituted alkyl, then R4 is B or substituted alkyl. These compounds are beta3 adrenergic receptor agonists and are useful, therefore for example, in the treatment of diabetes, obesity and gastrointestinal diseases.

  式中的化合物 或其药学上可接受的盐类，其中 A 是键、-(CH2)n- 或 -CH(B)-，其中 n 是 1 至 3 的整数，B 是 -CN、-CON(R9)R9' 或 -C02R7； R1 是低级烷基、芳基或芳烷基； R2 是氢、羟基、烷氧基、-CH20H、氰基、-C(O)OR7、-C02H、-CONH2、四唑、-CH2NH2 或卤素； R3 是氢、烷基、杂环或卤素。 R4 是氢、烷基或 B； R5、R5'、R8、R8' 或 R8'' 独立地为氢、烷氧基、低级烷基、卤素、-OH、-CN、-(CH2)-nNR6COR7、-CON(R6)R6'、-C02R6、-SR7、-SOR7、-S02R7、-N(R6)SO2R1、-N(R6)R6'、-NR6COR7、-OCH2CON(R6)R6'、-OCH2CO2R7 或芳基；或 R5 和 R5' 或 R8 和 R8'可与它们所连接的碳原子一起形成芳基或杂环； R6 和 R6'独立地为氢或低级烷基；以及 R7 是低级烷基； R9是氢、低级烷基、烷基、环烷基、芳烷基、芳基、杂芳基；或 R9和R9'可与它们所连接的氮原子一起形成一个杂环；但当A是键或-(CH2)n且R3是氢或未取代的烷基时，则R4是B或取代的烷基。这些化合物是β3肾上腺素能受体激动剂，因此可用于治疗糖尿病、肥胖症和胃肠道疾病等。